Want to see TSE:CSCI full AI Analyst Report?
CSCI Stock Chart & Stats
C$7.70
-C$0.05(-0.65%)
At close: 4:00 PM EDT
C$7.70
-C$0.05(-0.65%)
Day’s Range― - ―
52-Week RangeC$3.30 - C$14.80
Previous CloseN/A
Volume1.00
Average Volume (3M)2.48K
Market Cap
C$7.48M
Enterprise Value-C$1.80
Total Cash (Recent Filing)C$5.01M
Total Debt (Recent Filing)C$2.02M
Price to Earnings (P/E)―
Beta2.65
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-15.42
Shares Outstanding1,061,386
10 Day Avg. Volume3,973
30 Day Avg. Volume2,485
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.57
Price to Sales (P/S)0.29
P/FCF Ratio-0.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageA low debt-to-equity (~0.13) means the company carries limited interest and principal obligations relative to equity. This durable balance-sheet characteristic reduces bankruptcy and refinancing urgency, giving management flexibility to fund operations or R&D from equity or partnerships over months.
Improving Trailing Revenue TrendPositive TTM revenue growth (~6.3%) signals improving top-line traction versus prior periods. Sustained revenue expansion supports eventual operating leverage, strengthens commercial validation, and can reduce future funding needs if trends persist across product cycles over the medium term.
Lean Operating FootprintA small headcount (28 employees) implies a lean cost base and lower fixed payroll burden. Over 2-6 months this structural efficiency can extend cash runway, allow targeted hiring for priority programs, and preserve capital while management focuses on high-impact clinical or commercial milestones.
Bears Say
Persistent Negative Cash FlowSizable negative operating and free cash flow (~-$8.7M) indicates ongoing cash burn that is likely to continue absent material operational improvements. This structural outflow necessitates external financing or dilution, constrains strategic optionality, and increases execution risk over months.
Deep Operating Losses And MarginsExtremely negative EBIT/EBITDA and net margins reflect that core operations consume far more resources than they currently generate. Such deeply negative profitability is unlikely to reverse quickly and undermines sustainable cash generation until meaningful revenue scale or cost restructuring occurs.
Volatile Equity And Dilution RiskDocumented volatility in equity levels suggests prior or potential future capital raises and dilution. Given persistent losses and cash burn, the company may need to issue equity or take on financing, which can dilute shareholders and reflect ongoing dependency on external capital to sustain operations.
COSCIENS Biopharma News
CSCI FAQ
What was COSCIENS Biopharma’s price range in the past 12 months?
COSCIENS Biopharma lowest stock price was C$3.30 and its highest was C$14.80 in the past 12 months.
What is COSCIENS Biopharma’s market cap?
COSCIENS Biopharma’s market cap is C$7.48M.
When is COSCIENS Biopharma’s upcoming earnings report date?
COSCIENS Biopharma’s upcoming earnings report date is Aug 13, 2026 which is in 3 days.
How were COSCIENS Biopharma’s earnings last quarter?
COSCIENS Biopharma released its earnings results on May 12, 2026. The company reported -C$0.702 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is COSCIENS Biopharma overvalued?
According to Wall Street analysts COSCIENS Biopharma’s price is currently Overvalued.
Does COSCIENS Biopharma pay dividends?
COSCIENS Biopharma does not currently pay dividends.
What is COSCIENS Biopharma’s EPS estimate?
COSCIENS Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does COSCIENS Biopharma have?
COSCIENS Biopharma has 1,061,386 shares outstanding.
What happened to COSCIENS Biopharma’s price movement after its last earnings report?
COSCIENS Biopharma reported an EPS of -C$0.702 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.896%.
Which hedge fund is a major shareholder of COSCIENS Biopharma?
Currently, no hedge funds are holding shares in TSE:CSCI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
COSCIENS Biopharma
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a functional ingredient that supports overall health and wellness; oat powder and peptides; oat oil which is extracted from whole oat kernels by a gentle process that retains all the important biologically active components; and avenanthramides, a natural-based ingredients used to inflammation-based diseases for the cosmeceutical and pharmaceutical industries. It also provides Macrilen/Ghryvelin (macimorelin), an orally active peptidomimetic small molecule that stimulates the secretion of growth hormone from the pituitary gland. The company sells its products through its distribution network. It has license agreements with Pharmanovia, Davimed GmbH, and NK MEDITECH Ltd, as well as Agriculture Canada, Canadian Government, and University of Alberta. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.
Technical Analysis
BetterLife Pharma
―
PharmaTher Holdings Ltd
―
Glow LifeTech
―
Marvel Biosciences Corp
―
PharmAla Biotech Holdings, Inc.
―